What is your treatment of choice in ALK-positive lung adenocarcinomas that have progressed on alectinib with resistance mutations that are not G1202R?
Do you choose Lorlatinib or brigatinib? Or do you try to add chemotherapy to alectinib?
Community PollStarted
What is your next choice for ALK+ lung adenoca which has non-G1202R resistance mutations post-alectinib?
35 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · University of Colorado Cancer Center
Answered on
Lorlatinib has high response rates with any resistance mechanism.
Join for free or sign in to see the full answer
Mednet Member
Medical Oncology · Boston Med Center
Answered on
Data regarding use of lorlatinib after 1st or 2nd generation ALK-TKI failure comes from a phase II trial that enrolled multiple cohorts based on number/type of treatments received (i.e., 1st or 2nd gen. ALK-TKI with or without chemotherapy) (Shaw et al., PMID 30892989).
In this study, patients who ha...
Join for free or sign in to see the full answer